Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

AstraZeneca inks cancer therapy deal with Singapore-based research center
September 2008
SHARING OPTIONS:

LONDON—AstraZeneca announced in August it has partnered with the National Cancer Centre Singapore (NCCS) and the National University Hospital (NUH) to develop therapies for hepatocellular carcinoma (HCC), a type of cancer that is particularly prevalent in Asia and accounts for approximately 1 million deaths annually worldwide.

The partnership includes a training program placement with the Manchester Cancer Research Centre. AstraZeneca will give NCCS and NUH access to compounds that have already undergone initial clinical testing in the West. As part of the deal, AstraZeneca retains the option to assume further development and marketing of all drugs made available. Financial terms of the agreement were not disclosed. DDN

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2019 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.